Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...
GlobalData on MSN8d
Boehringer Ingelheim announces Phase III schizophrenia failuresThe company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...
Boehringer healthcare HCP Illustrative image Boehringer Ingelheim today announced top-line results from the Phase III CONNEX ...
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...
The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback